AR053450A1 - Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38 - Google Patents
Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38Info
- Publication number
- AR053450A1 AR053450A1 ARP060101148A ARP060101148A AR053450A1 AR 053450 A1 AR053450 A1 AR 053450A1 AR P060101148 A ARP060101148 A AR P060101148A AR P060101148 A ARP060101148 A AR P060101148A AR 053450 A1 AR053450 A1 AR 053450A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- cycloalkyl
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
Abstract
Reivindicacion 1: Un compuesto de formulas (1) y (29 en las que G1 y G2 son independientemente N; G3 es NH; G4 es N; R1 es C(Z)N(R10')(CR10R20)vRb, C(Z)O(CR10R20)vRb, N(R10')C(Z)(CR10R20)vRb; N(R10')C(Z)N(R10')(CR10R20)vRb; o N(R10')OC(Z) (CR10R20)vRb; R1' se selecciona independientemente en cada caso entre halogeno, alquilo C1-4, alquilo C1-4 sustituido con halo, ciano, nitro, (CR10R20)v'NRdRd'; (CR10R20)v'C(O)R12, SR5, S(O)R5, S(O)2R5 o (CR10R20)v'OR13; Rb es un resto H, alquilo C1-10, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-10, arilo, aril-alquilo C1-10, heteroarilo, heteroaril-alquiloC1-10, heterociclo o heterociclil- alquilo C1-10, en el que los restos, excluyendo el H, pueden estar todos opcionalmente sustituidos; X es R2, OR2', S(O)mR2', (CH2) n'N(R10')S(O)mR2', (CH2)n'N(R10')C(O)R2', (CH2)n'NR4R14, (CH2)n'N(R2')(R2ö) o N(R10')-Rh-NH-C(=N-CN)NRqRq'; X1 es N(R11), O, S(O)m o CR10R20; Rh se selecciona entre un alquilo C1-10 opcionalmente sustituido -CH2-C(O)-CH2-, -CH2-O-CH2-, -CH2-C(O)N(R10') CH2-CH2-, -CH2-N(R10')C(O)CH2-, -CH2-CH(OR10')-CH2-, -CH2-C(O)O-CH2-CH2- o -CH2-CH2-O-C(O)CH2-; Rq y Rq' se seleccionan independientemente en cada caso entre un resto H, alquilo C1-10, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-10, cicloalquenilo C5-7, cicloalquenil C5-7-alquilo C1-10, arilo, aril-alquilo C1-10, heteroarilo, heteroaril-alquilo C1-10, heterociclo o heterociclil-alquilo C1-10, en los que todos los restos, excluyendo el H, están opcionalmente sustituidos, o Rq y Rq' junto con el N al que están unidos, forman un anillo opcionalmente sustituido de 5 a 7 miembros, donde el anillo puede contener un heteroátomo adicional seleccionado entre O, N o S; R2 es un resto H, alquilo C1- 10, cicloalquilo C3-7, cicloalquilalquilo C3-7, arilo, aril-alquilo C1-10, heteroarilo, heteroaril-alquilo C1-10, heterociclilo o heterociclil-alquilo C1-10, y en el que cada uno de estos restos, excluyendo el H, puede estar opcionalmente sustituido; o R2 es el resto (CR10R20)q'X1(CR10R20)qC(A1)(A2)(A3) o (CR10R20)q'C(A1)(A2)(A3); R2' es un resto H, alquilo C1-10, cicloalquilo C3-7, cicloalquilalquilo C3-7, arilo, aril-alquilo C1-10, heteroarilo, heteroaril-alquilo C1-10, heterociclilo o heterociclil-alquilo C1-10, y en el que cada uno de estos restos, excluyendo el H, puede estar opcionalmente sustituido; R2ö es un resto H, alquilo C1-10, cicloalquilo C3-7, cicloalquilalquilo C3-7, arilo, aril-alquilo C1-10, heteroarilo, heteroaril-alquilo C1-10, heterociclilo o heterociclil-alquilo C1-10, y en el que estos restos, excluyendo el H, pueden estar opcionalmente sustituidos; o donde R2ö es el resto (CR10R20) tX1(CR10R20)qC(A1)(A2)(A3); A1 es un alquilo C1-10 opcionalmente sustituido, heterociclo, heterocicloalquilo C1-10, heteroarilo, heteroaril-alquilo C1-10, arilo o aril-alquilo C1-10; A2 es un alquilo C1-10 opcionalmente sustituido, heterociclo, heterocicloalquilo C1-10, heteroarilo, heteroaril- alquilo C1-10, arilo o aril-alquilo C1-10; A3 es H o es un alquilo C1-10 opcionalmente sustituido; R3 es un resto alquilo C1-10, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-10, arilo, aril-alquilo C1-10, heteroaril-alquilo C1-10, o heterociclil- alquilo C1-10, y en el que cada uno de estos restos pueden estar opcionalmente sustituido; R4 y R14 se seleccionan cada uno independientemente en cada caso entre un resto H, alquilo C1-10, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-4, arilo, aril-alquilo C1-4, heterociclo, heterocicloalquilo C1-4, heteroarilo o heteroaril-alquilo C1-4, y en los que cada uno de estos restos, excluyendo el H, puede estar opcionalmente sustituido; o R4 y R14 junto con el N al que están unidos, forman un anillo heterocíclico opcionalmente sustituido de 4 a 7 miembros, en donde el anillo opcionalmente contiene un heteroátomo adicional seleccionado entre O, S o N; R4' y R14' se seleccionan independientemente en cada caso entre H o alquilo C1-4, o R4' y R14' junto con el N al que están unidos, forman un anillo heterocíclico de 5 a 7 miembros, donde el anillo opcionalmente contiene un heteroátomo adicional seleccionado a partir de NR9'; R5 se selecciona independientemente en cada caso entre H, alquilo C1-4, alquenilo C2-4, alquinilo C2-4 o NR4'R14', excluyendo los restos SR5 que son SNR4'R14'; S(O)2R5 que son SO2H y S(O)R5 que son SOH; R9' se selecciona independientemente en cada caso entre H o alquilo C1-4; R10 y R20 se seleccionan independientemente en cada caso entre H o alquilo C1-4; R10' se selecciona independientemente en cada caso entre H o alquilo C1-4; R11 se selecciona independientemente en cada caso entre H o alquilo C1-4; R12 se selecciona independientemente en cada caso entre un resto H, alquilo C1-4, alquilo C1-4 sustituido con halo, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-4, cicloalquenilo C5-7, cicloalquenil C5-7-alquilo C1-4, arilo, aril-alquilo C1-4, heteroarilo, heteroaril-alquilo C1-4, heterociclilo o heterociclil-alquilo C1-4, y en el que cada uno de estos restos, excluyendo el H, puede estar opcionalmente sustituido; R13 se selecciona independientemente en cada caso entre un resto H, alquilo C1-4, alquilo C1-4 sustituido con halo, alquenilo C2-4, alquinilo C2-4, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-4, cicloalquenilo C5-7, cicloalquenil C5-7- alquilo C1-4, arilo, aril-alquilo C1-4, heteroarilo, heteroaril-alquilo C1-4, heterociclilo o heterociclil-alquilo C1-4, y en el que cada uno de estos restos, excluyendo el H, puede estar opcionalmente sustituido; cada uno de Rd y Rd' se selecciona independientemente en cada caso entre un resto H, alquilo C1-4, cicloalquilo C3-6, cicloalquil C3-6-alquilo C1-4 y en los que cada uno de estos restos, excluyendo el H, puede estar opcionalmente sustituido; o Rd y Rd' junto con el N al que están unidos forman un anillo heterocíclico opcionalmente sustituido de 5 a 6 miembros, donde dicho anillo contiene opcionalmente un heteroátomo más seleccionado entre O, S o NR9'; g es 0 o un numero entero que tiene el valor 1, 2, 3, o 4; n' se selecciona independientemente en cada caso entre 0 y un numero entero que tiene un valor de 1 a 10; m se selecciona independientemente en cada caso entre 0 y un entero que tiene un valor de 1 o 2; q es 0 o un entero que tiene un valor de 1 a 10; q' es 0 o un numero entero que tiene un valor de 1 a 6; t es un numero entero que tiene un valor de 2 a 6; v es 0 o un numero entero que tiene el valor 1 o 2; v' se selecciona independientemente en cada caso entre 0 o un entero que tiene un valor de1 o 2; Z se selecciona independientemente en cada caso entre O o S; o una de sus sales farmacéuticamente aceptables, solvatos o derivados fisiologicamente funcionales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66534705P | 2005-03-25 | 2005-03-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR053450A1 true AR053450A1 (es) | 2007-05-09 |
Family
ID=37053936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060101148A AR053450A1 (es) | 2005-03-25 | 2006-03-23 | Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38 |
Country Status (23)
Country | Link |
---|---|
US (4) | US7674789B2 (es) |
EP (1) | EP1866311A4 (es) |
JP (1) | JP2008535820A (es) |
KR (1) | KR20080005223A (es) |
CN (1) | CN101184758B (es) |
AP (1) | AP2281A (es) |
AR (1) | AR053450A1 (es) |
AU (1) | AU2006229967B2 (es) |
BR (1) | BRPI0609579A2 (es) |
CA (1) | CA2602546A1 (es) |
EA (1) | EA200702074A1 (es) |
IL (1) | IL185915A0 (es) |
MA (1) | MA29340B1 (es) |
MX (1) | MX2007011883A (es) |
NO (1) | NO20075273L (es) |
NZ (1) | NZ561438A (es) |
PE (2) | PE20100741A1 (es) |
SG (1) | SG166100A1 (es) |
TW (1) | TW200724142A (es) |
UA (1) | UA95230C2 (es) |
UY (1) | UY29439A1 (es) |
WO (1) | WO2006104889A2 (es) |
ZA (1) | ZA200707798B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
CN100525768C (zh) | 2000-10-23 | 2009-08-12 | 史密丝克莱恩比彻姆公司 | 新化合物 |
ATE375980T1 (de) | 2002-02-12 | 2007-11-15 | Smithkline Beecham Corp | Nicotinamide und deren verwendung als p38 inhibitoren |
EP1499320B1 (en) * | 2002-04-19 | 2007-08-22 | Smithkline Beecham Corporation | Novel compounds |
KR20080002865A (ko) * | 2005-03-25 | 2008-01-04 | 글락소 그룹 리미티드 | 피리도[2,3-d]피리미딘-7-온 및3,4-디히드로피리미도[4,5-d]피리미딘-2(1h)-온유도체의 제조 방법 |
TW200724142A (en) * | 2005-03-25 | 2007-07-01 | Glaxo Group Ltd | Novel compounds |
PE20100737A1 (es) * | 2005-03-25 | 2010-11-27 | Glaxo Group Ltd | Nuevos compuestos |
US20090137550A1 (en) * | 2005-03-25 | 2009-05-28 | Glaxo Group Limited | Novel Compounds |
EP2034838A4 (en) * | 2006-06-16 | 2012-01-04 | Glaxo Group Ltd | NOVEL CONNECTIONS |
WO2007147109A2 (en) * | 2006-06-16 | 2007-12-21 | Glaxo Group Limited | Novel compounds |
US20100069409A1 (en) * | 2006-06-16 | 2010-03-18 | Glaxo Group Limited | "novel compounds" |
AU2007346136B2 (en) * | 2007-02-09 | 2012-10-25 | Corteva Agriscience Llc | Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
CA2726158A1 (en) * | 2008-06-11 | 2009-12-17 | Dana Farber Cancer Institute | Compounds and compositions useful for the treatment of malaria |
CN103827118B (zh) * | 2011-07-27 | 2016-03-09 | 葛兰素集团有限公司 | 双环嘧啶酮化合物 |
SG11202003035SA (en) | 2017-10-05 | 2020-04-29 | Fulcrum Therapeutics Inc | Use of p38 inhibitors to reduce expression of dux4 |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CN111961034A (zh) * | 2019-05-20 | 2020-11-20 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
CN113750095B (zh) * | 2021-03-10 | 2023-07-04 | 中国医学科学院医药生物技术研究所 | 含有环丙基骨架的化合物在制备治疗和/或预防冠状病毒感染药物中的应用 |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA966134A (en) * | 1972-05-05 | 1975-04-15 | Haydn W.R. Williams | 1,8-naphthyridine compounds |
ZA803539B (en) * | 1979-06-14 | 1982-01-27 | Wellcome Found | Alkoxybenzylrimidines method for their preparation formulation thereof and their use in medicine |
GB2064336B (en) | 1979-12-06 | 1984-03-14 | Glaxo Group Ltd | Device for dispensing medicaments |
US4353656A (en) | 1980-10-14 | 1982-10-12 | Xerox Corporation | Moving coil, multiple energy print hammer system including a closed loop servo |
EP0069715B1 (en) | 1981-07-08 | 1986-11-05 | Aktiebolaget Draco | Powder inhalator |
GB2123831B (en) | 1981-07-20 | 1986-01-15 | Ciba Geigy Ag | Trisubstituted oxazo compounds |
AT396333B (de) | 1982-10-08 | 1993-08-25 | Glaxo Group Ltd | Vorrichtung zur verabreichung von medikamenten an patienten, einrichtung mit mehreren solchen vorrichtungen und traeger mit medikamentbehaeltern hiefuer |
US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
JPS60226882A (ja) * | 1984-04-24 | 1985-11-12 | Nippon Zoki Pharmaceut Co Ltd | 新規ピリミドピリミジン誘導体 |
US4560691A (en) * | 1984-07-13 | 1985-12-24 | Sterling Drug Inc. | 5-(Phenyl)-1,6-naphthyridin-2(1H)-ones, their cardiotonic use and preparation |
DK163640C (da) | 1985-07-30 | 1992-08-17 | Glaxo Group Ltd | Apparat til administrering af medikamenter |
EP0278686A1 (en) | 1987-02-07 | 1988-08-17 | The Wellcome Foundation Limited | Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof |
JPH01261306A (ja) | 1988-04-13 | 1989-10-18 | Nippon Kayaku Co Ltd | 2−アルキルチオ−4−アミノピリミジン誘導体を有効成分とする開花促進剤 |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
IE913473A1 (en) * | 1990-10-15 | 1992-04-22 | Fujisawa Pharmaceutical Co | Quinazoline derivatives and their preparation |
JPH06502178A (ja) | 1990-12-31 | 1994-03-10 | 藤沢薬品工業株式会社 | イミダゾトリアジン誘導体 |
DK0584222T3 (da) * | 1991-05-10 | 1998-02-23 | Rhone Poulenc Rorer Int | Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase |
IL102764A0 (en) | 1991-08-16 | 1993-01-31 | Merck & Co Inc | Quinazoline derivatives,and pharmaceutical compositions containing them |
DE4131029A1 (de) * | 1991-09-18 | 1993-07-29 | Basf Ag | Substituierte pyrido (2,3-d) pyrimidine als antidots |
GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
GB9303993D0 (en) | 1993-02-26 | 1993-04-14 | Fujisawa Pharmaceutical Co | New heterocyclic derivatives |
US5466692A (en) * | 1993-03-24 | 1995-11-14 | American Home Products Corporation | Substituted pyridopyrimidines and antihypertensives |
US5426110A (en) * | 1993-10-06 | 1995-06-20 | Eli Lilly And Company | Pyrimidinyl-glutamic acid derivatives |
GB9325217D0 (en) | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
US5547954A (en) * | 1994-05-26 | 1996-08-20 | Fmc Corporation | 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides |
TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
ATE191470T1 (de) | 1994-06-15 | 2000-04-15 | Wellcome Found | Enzymhemmer |
KR970705562A (ko) * | 1994-08-29 | 1997-10-09 | 오노다 마사요시 | 신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof) |
IL115256A0 (en) * | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
US5772085A (en) | 1995-03-10 | 1998-06-30 | Minnesota Mining And Manufacturing | Free flow aerosol valves |
US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
US5760220A (en) * | 1995-06-07 | 1998-06-02 | American Home Products Corporation | Process for preparation of biphenyl derivatives |
US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
EP0892795B1 (en) | 1996-04-12 | 2003-01-08 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyramidine derivatives |
ZA973884B (en) * | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
US6875769B2 (en) * | 1996-05-23 | 2005-04-05 | Pfizer Inc. | Substituted6,6-hetero-bicyclicderivatives |
PL331602A1 (en) * | 1996-08-06 | 1999-08-02 | Pfizer | Pyrido- or pyrimido-substituted 6,6- or 6,7-bicyclic derivatives |
TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
US6509320B1 (en) * | 1996-10-16 | 2003-01-21 | Icn Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses thereof |
US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
GB9700226D0 (en) | 1997-01-08 | 1997-02-26 | Glaxo Group Ltd | Inhalation device |
MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
CA2271157A1 (en) | 1997-02-05 | 1998-08-06 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
US5945422A (en) * | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
AU1924699A (en) | 1997-12-19 | 1999-07-12 | Smithkline Beecham Corporation | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses |
US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
KR20010041015A (ko) * | 1998-02-17 | 2001-05-15 | 윌리엄 제이. 리플린 | 항바이러스성 피리미딘 유도체 |
JP2000038350A (ja) | 1998-05-18 | 2000-02-08 | Yoshitomi Pharmaceut Ind Ltd | 糖尿病治療薬 |
US6248225B1 (en) * | 1998-05-26 | 2001-06-19 | Ppg Industries Ohio, Inc. | Process for forming a two-coat electrodeposited composite coating the composite coating and chip resistant electrodeposited coating composition |
YU73300A (sh) | 1998-05-26 | 2003-08-29 | Warner-Lambert Company | Biciklični pirimidini i biciklični 3,4-dihidropirimidini kao inhibitori ćelijske proliferacije |
GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
JP2002517486A (ja) * | 1998-06-12 | 2002-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | p38のインヒビター |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
CA2341374A1 (en) * | 1998-10-01 | 2000-04-13 | Astrazeneca Ab | Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases |
WO2000023444A1 (en) | 1998-10-21 | 2000-04-27 | Abbott Laboratories | 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
US6358959B1 (en) | 1999-01-26 | 2002-03-19 | Merck & Co., Inc. | Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists |
AU4501800A (en) | 1999-05-04 | 2000-11-17 | American Home Products Corporation | Tetracyclic progesterone receptor modulator compounds and methods |
CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
ATE380814T1 (de) | 1999-09-17 | 2007-12-15 | Abbott Gmbh & Co Kg | Kinaseinhibitoren als arzneimittel |
AU2576501A (en) | 1999-12-08 | 2001-06-18 | Advanced Medicine, Inc. | Protein kinase inhibitors |
US6632666B2 (en) | 2000-01-14 | 2003-10-14 | Biolife Solutions, Inc. | Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media |
CZ20022475A3 (cs) | 2000-01-25 | 2003-03-12 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidin-2,7-diaminové inhibitory kinázy |
PL357634A1 (en) * | 2000-01-27 | 2004-07-26 | Warner-Lambert Company | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
CZ20022929A3 (cs) | 2000-03-06 | 2003-02-12 | Warner-Lambert Company | 5-Alkylpyrido[2,3-d]pyrimidinové inhibitory tyrosinových kinas |
KR20040041082A (ko) * | 2000-07-24 | 2004-05-13 | 비브콤 인코포레이티드 | 멀티미디어 북마크와 비디오의 가상 편집을 위한 시스템및 방법 |
PL362711A1 (en) | 2000-09-29 | 2004-11-02 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
WO2002060869A2 (en) | 2000-10-19 | 2002-08-08 | Smithkline Beecham Corporation | Use of p38 inhibitors for the treatment of inflammation-enhanced cough |
CN100525768C (zh) * | 2000-10-23 | 2009-08-12 | 史密丝克莱恩比彻姆公司 | 新化合物 |
AU2002246677B2 (en) * | 2000-12-20 | 2006-11-16 | Merck Sharp & Dohme Corp. | (Halo-Benzo Carbonyl)Heterocyclo Fused Phenyl p38 Kinase Inhibiting Agents |
GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
WO2003010143A1 (en) | 2001-07-26 | 2003-02-06 | Samsung Electronics Co., Ltd. | Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses |
JP4178783B2 (ja) | 2001-10-19 | 2008-11-12 | 三菱化学株式会社 | 光学記録媒体 |
US7019002B2 (en) * | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
EP1467982B8 (en) | 2002-01-14 | 2007-04-11 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof |
DE60303009T2 (de) * | 2002-01-22 | 2006-07-13 | Warner-Lambert Co. Llc | 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one |
EP1467730A4 (en) | 2002-01-22 | 2010-03-10 | Univ California | Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof |
DK1490062T3 (da) | 2002-03-26 | 2008-04-28 | Boehringer Ingelheim Pharma | Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf |
WO2003082787A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
CA2481320A1 (en) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
WO2003093290A2 (en) * | 2002-05-06 | 2003-11-13 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
AU2003281355A1 (en) | 2002-07-08 | 2004-01-23 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
AU2003251969A1 (en) | 2002-07-18 | 2004-02-09 | Bristol-Myers Squibb Company | Compositions and methods involving nuclear hormone receptor site ii |
PL375442A1 (en) | 2002-07-18 | 2005-11-28 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
CA2496175A1 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
AU2003270783C1 (en) | 2002-09-20 | 2010-05-20 | Merck Sharp & Dohme Corp. | Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
WO2004043367A2 (en) * | 2002-11-06 | 2004-05-27 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and use thereof |
JP2004203751A (ja) | 2002-12-24 | 2004-07-22 | Pfizer Inc | 置換6,6−ヘテロ二環式誘導体 |
DE602004021558D1 (de) * | 2003-01-17 | 2009-07-30 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
MXPA05008612A (es) | 2003-02-14 | 2005-12-05 | Smithkline Beecham Corp | Compuestos novedosos. |
US7138412B2 (en) * | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
EP1636195A1 (en) * | 2003-05-27 | 2006-03-22 | Pfizer Products Inc. | Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors |
TWI220897B (en) * | 2003-07-22 | 2004-09-11 | Benq Corp | Recording media feeding system and method |
CN1894222A (zh) | 2003-08-05 | 2007-01-10 | 沃泰克斯药物股份有限公司 | 作为电压门控离子通道抑制剂的稠合嘧啶化合物 |
US7098222B2 (en) * | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
WO2006039469A1 (en) * | 2004-09-29 | 2006-04-13 | Graphic Packaging International, Inc | Carton with dispenser having access features |
CA2590294A1 (en) * | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
PE20100737A1 (es) * | 2005-03-25 | 2010-11-27 | Glaxo Group Ltd | Nuevos compuestos |
US20090137550A1 (en) * | 2005-03-25 | 2009-05-28 | Glaxo Group Limited | Novel Compounds |
TW200724142A (en) * | 2005-03-25 | 2007-07-01 | Glaxo Group Ltd | Novel compounds |
KR20080002865A (ko) * | 2005-03-25 | 2008-01-04 | 글락소 그룹 리미티드 | 피리도[2,3-d]피리미딘-7-온 및3,4-디히드로피리미도[4,5-d]피리미딘-2(1h)-온유도체의 제조 방법 |
-
2006
- 2006-03-23 TW TW095109982A patent/TW200724142A/zh unknown
- 2006-03-23 UY UY29439A patent/UY29439A1/es unknown
- 2006-03-23 PE PE2010000198A patent/PE20100741A1/es not_active Application Discontinuation
- 2006-03-23 PE PE2006000331A patent/PE20061193A1/es not_active Application Discontinuation
- 2006-03-23 AR ARP060101148A patent/AR053450A1/es not_active Application Discontinuation
- 2006-03-24 AP AP2007004171A patent/AP2281A/xx active
- 2006-03-24 BR BRPI0609579-8A patent/BRPI0609579A2/pt not_active IP Right Cessation
- 2006-03-24 UA UAA200710644A patent/UA95230C2/ru unknown
- 2006-03-24 SG SG201006926-8A patent/SG166100A1/en unknown
- 2006-03-24 US US11/389,112 patent/US7674789B2/en not_active Expired - Fee Related
- 2006-03-24 MX MX2007011883A patent/MX2007011883A/es active IP Right Grant
- 2006-03-24 CN CN2006800183985A patent/CN101184758B/zh not_active Expired - Fee Related
- 2006-03-24 KR KR1020077024433A patent/KR20080005223A/ko not_active Application Discontinuation
- 2006-03-24 JP JP2008503226A patent/JP2008535820A/ja active Pending
- 2006-03-24 WO PCT/US2006/010792 patent/WO2006104889A2/en active Application Filing
- 2006-03-24 EP EP06748656A patent/EP1866311A4/en not_active Withdrawn
- 2006-03-24 AU AU2006229967A patent/AU2006229967B2/en not_active Ceased
- 2006-03-24 US US11/908,435 patent/US20090239846A1/en not_active Abandoned
- 2006-03-24 CA CA002602546A patent/CA2602546A1/en not_active Abandoned
- 2006-03-24 NZ NZ561438A patent/NZ561438A/en not_active IP Right Cessation
- 2006-03-24 EA EA200702074A patent/EA200702074A1/ru unknown
-
2007
- 2007-09-11 IL IL185915A patent/IL185915A0/en unknown
- 2007-09-12 ZA ZA200707798A patent/ZA200707798B/xx unknown
- 2007-09-24 MA MA30236A patent/MA29340B1/fr unknown
- 2007-10-15 NO NO20075273A patent/NO20075273L/no not_active Application Discontinuation
-
2009
- 2009-11-16 US US12/618,927 patent/US20100093765A1/en not_active Abandoned
- 2009-11-16 US US12/618,933 patent/US20100093766A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
UY29439A1 (es) | 2006-10-02 |
ZA200707798B (en) | 2009-08-26 |
PE20061193A1 (es) | 2006-12-02 |
IL185915A0 (en) | 2008-01-06 |
US20100093766A1 (en) | 2010-04-15 |
AU2006229967B2 (en) | 2012-02-09 |
CN101184758A (zh) | 2008-05-21 |
NZ561438A (en) | 2011-02-25 |
JP2008535820A (ja) | 2008-09-04 |
NO20075273L (no) | 2007-12-12 |
US7674789B2 (en) | 2010-03-09 |
US20100093765A1 (en) | 2010-04-15 |
EP1866311A2 (en) | 2007-12-19 |
WO2006104889A2 (en) | 2006-10-05 |
CA2602546A1 (en) | 2006-10-05 |
KR20080005223A (ko) | 2008-01-10 |
AP2281A (en) | 2011-10-31 |
AU2006229967A1 (en) | 2006-10-05 |
CN101184758B (zh) | 2012-05-02 |
UA95230C2 (ru) | 2011-07-25 |
MX2007011883A (es) | 2007-11-13 |
US20090239846A1 (en) | 2009-09-24 |
BRPI0609579A2 (pt) | 2010-04-20 |
SG166100A1 (en) | 2010-11-29 |
PE20100741A1 (es) | 2010-11-25 |
TW200724142A (en) | 2007-07-01 |
US20060235030A1 (en) | 2006-10-19 |
EA200702074A1 (ru) | 2008-02-28 |
AP2007004171A0 (en) | 2007-10-31 |
EP1866311A4 (en) | 2010-03-31 |
MA29340B1 (fr) | 2008-03-03 |
WO2006104889A3 (en) | 2007-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR053450A1 (es) | Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38 | |
AR053346A1 (es) | Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38 | |
AR056218A1 (es) | Composicion farmaceutica de liberacion mantenida comprimido de liberacion inmediata y comprimido oralmente administrable que comprende una sla soluble en agua d 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2- hidroxi-1-(hidroximetil)etil] amino}pirido (2,3-d)pirimidin-7(8h)-ona; dicho compues | |
CO5580778A2 (es) | Derivados de lactama como antagonistas para receptores 11cby humanos | |
CO5540344A2 (es) | Medicamentos | |
AR056876A1 (es) | Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares | |
AR059937A1 (es) | Compuesto de pirido (2,3-d) pirimidin -7-ona o compuesto que contiene 3,4- dihidropirimido (4,5-d) pirimidin -2 (1h) -ona y proceso para su preparacion | |
NO20073729L (no) | Heterocykliske forbindelser som CCR2B-antagonister | |
AR049708A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
ECSP12006640A (es) | Inhibidores heterocíclicos de aspartil proteasa | |
AR049706A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
AR049331A1 (es) | Derivados de imidazopiridinas, imidazoquinolinas e iimidazonaftiridinas sustituidas con amidas como moduladores de biosintesis de citoquinas. composiciones farmaceuticas. | |
AR033290A1 (es) | Derivados antiinflamatorios de androstano | |
CO5650168A2 (es) | Nuevos peptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c | |
AR053202A1 (es) | Pirazolpiridinas y analogos de las mismas como inmunomoduladores | |
AR056875A1 (es) | Ligandos del receptor vaniloide y su aplicacion para la fabricacion de medicamentos | |
AR059778A1 (es) | Compuestos de pirrolotriazina inhibidores de quinasas p38,composiciones farmaceuticas que los contienen y usos en gran variedad de procesos inflamatorios. | |
PA8603801A1 (es) | Derivados de la quinazolina | |
AR052312A1 (es) | 2- anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y medicamentos preparados en base al compuesto | |
AR054369A1 (es) | Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa | |
UY27109A1 (es) | Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b | |
AR064345A1 (es) | Derivados de 8-oxoadenina | |
AR069494A1 (es) | Derivados de acidos fosfonicos | |
UY29016A1 (es) | Analogos de dipeptidos inhibidores de la hepatitis c | |
AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |